Eli Lily and the chief of the company and CEO of Dave Rix, on growth and success, the increase in the popularity of weight loss drugs and Alzheimer's research.
Eli Lily is expanding the supply and reducing the cost of weight loss drugs, which increases access to more patients without insurance.
The company launched 7.5 mg and 10 mg Tirzepatide, which is sold under the Zepbound brand, which usually costs $ 599 and $ 699. However, they are now available for $ 499 per month for patients who pay without insurance. This is the first filling and all the fillings that are delivered every 45 days.
In addition, the company reduced the price of 2.5 mg and 5 mg to $ 349 and $ 499 per month, respectively.
The CEO of Sima Sistani's weightlifting hugged weight loss drugs
The company, which is witnessing a significant increase in profits from Zepbound and Moussjaro-is actually the same drug approved by the FDA-suggesting that new vials and pricing exclusively through the company's self-paying pharmacy, LillyDirect Self Pay Solutions are available for drug solutions. Human
The company said that the program itself eliminates the third -party supply chain institutions itself, “allows patients to directly access the savings outside the insurance.”
Eli Lily is expanding the supply and reducing the cost of weight loss drugs, which increases access to more patients without insurance. (Shelby Knowles / Bloomberg via / Getty Images)
“Every major medical organization and institute recognizes obesity as a chronic disease, but insurance and federal programs systematically have people who are obese for medical care Does not cover the Kend – this requires change. ” Human
Joneson said the company is “committed to working with all parties to solve this problem” and “will continue to implement new options that improve prices and availability” Blockster, which will continue to increase demand. .
This is not the first time Lily has expanded its supply Weight loss drug And reduce your cost for effective competition in the very lucrative market.
The study shows that Zepbound to Lily reduces the risk of type 2 diabetes.
In August, the giant announced that for the first time in response to increased demand, it offers 2.5 mg and 5 mg of single -dose vials. At that time, Lily said the doses were also priced at 50 % or more compared to the price list of other Incretin (GLP-1) drugs for obesity.
Eli Lily's headquarters in Indianapolis, Indiana. (ISTOCK / ISTOCK)
GLP-1 agonists are a class of type 2 diabetes that improve blood sugar control but may also lead to weight loss. SEMAGLUTIDE, which are active in Novo Nordisk's Wegovy and Ozempic as well as Tirzepatide GLP-1 drugs intendedHuman
Get Fox Business on a move by clicking here
Lily reported earlier this month that its revenue increased by 45 percent in the last quarter of the financial quarter, with its new products help more than $ 3.1 billion, mainly led by high demand for Monjuro and Zep.
| Tick | Security | The last | Change | Changing % |
|---|---|---|---|---|
| Lily | Eli Lily and Company. | 901.80 | +20.40 |
+2.31 % |
The company also reported that because more patients used direct lily, the absorption of disposable Zepbound vials increased during the three -month period.
“The wholesalers are making orders from pharmacies at very high levels,” CEO David Rix told analysts.
The drug is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg or 15 mg per dose 0.5 ml in a single dose.